Potentia eye drug's Phase I trials end with good results

05/4/2009 | American City Business Journals

Potentia Pharmaceuticals said POT-4, a treatment for age-related macular degeneration, was well-tolerated and did not cause adverse events or side effects in patients during a recently completed first-stage study. The biotech company is gearing up for midstage trials to test the safety and effectiveness of the drug.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL